Antonio Escartin

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates.

Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: October 07, 2017

The prevalence of narcolepsy in Catalunya (Spain).

The prevalence of narcolepsy in Catalunya (Spain).

Journal: Journal of sleep research

Published: July 14, 2017

Absence of antibodies against KIR4.1 in multiple sclerosis: A three-technique approach and systematic review.

Absence of antibodies against KIR4.1 in multiple sclerosis: A three-technique approach and systematic review.

Journal: PloS one

Published: September 05, 2016

Neurophysiological Evidence of Compensatory Brain Mechanisms in Early-Stage Multiple Sclerosis.

Neurophysiological Evidence of Compensatory Brain Mechanisms in Early-Stage Multiple Sclerosis.

Journal: PloS one

Published: May 19, 2015

Efficacy and safety of lacosamide as first add-on or later adjunctive treatment for uncontrolled partial-onset seizures: A multicentre open-label trial.

Efficacy and safety of lacosamide as first add-on or later adjunctive treatment for uncontrolled partial-onset seizures: A multicentre open-label trial.

Journal: Seizure

Published: April 28, 2015

A one-year follow-up study of the Symbol Digit Modalities Test (SDMT) and the Paced Auditory Serial Addition Test (PASAT) in relapsing-remitting multiple sclerosis: an appraisal of comparative longitudinal sensitivity.

A one-year follow-up study of the Symbol Digit Modalities Test (SDMT) and the Paced Auditory Serial Addition Test (PASAT) in relapsing-remitting multiple sclerosis: an appraisal of comparative longitudinal sensitivity.

Journal: BMC neurology

Published: October 03, 2014

Adverse events during the titration phase of interferon-beta in remitting-relapsing multiple sclerosis are not predicted by body mass index nor by pharmacodynamic biomarkers.

Adverse events during the titration phase of interferon-beta in remitting-relapsing multiple sclerosis are not predicted by body mass index nor by pharmacodynamic biomarkers.

Journal: BMC neurology

Published: February 12, 2013

Spanish multi-centre observational study of the first attacks suggestive of multiple sclerosis: the PREM cohort

Spanish multi-centre observational study of the first attacks suggestive of multiple sclerosis: the PREM cohort

Journal: Revista de neurologia

Published: November 05, 2011

Showing 1-8 of 8

Last Updated: 09/26/2026